70-Gene Signature Assay Impacts Treatment Decisions in Breast Cancer

Share this content:
Receiving the 70-GS classifications was associated with a significant change in adjuvant treatment decision, researchers determined.
Receiving the 70-GS classifications was associated with a significant change in adjuvant treatment decision, researchers determined.

(HealthDay News) -- The 70-gene signature (GS) assay affects treatment decisions among physicians treating patients identified as being at intermediate risk with the 21-gene assay (21-GA), according to a study published online Oct. 26 in JAMA Oncology.

Michaela Tsai, M.D., from the Virginia Piper Cancer Center in Minneapolis, and colleagues conducted a study involving 840 patients with early-stage breast cancer and a 21-gene assay recurrence score of 18 to 30. Physicians were given the 70-GS result before adjuvant treatment, and the change in physician treatment decision was assessed before versus after receiving the result.

The researchers found that receiving the 70-GS classifications was correlated with a significant change in adjuvant treatment decision, with an odds ratio of 0.64 for all patients. Overall, 28.9 percent of low-risk patients had chemotherapy removed from the treatment recommendation, while 36.7 percent of high-risk patients had chemotherapy added. Results of the 70-GS were associated with the physician's adjuvant treatment recommendation; 87.8 percent of high-risk and 90.6 percent of low-risk patients were recommended to receive adjuvant chemotherapy or no chemotherapy, respectively. In 78.6 percent of cases, physicians reported having more confidence in their treatment recommendations based on 70-GS results.

"The 70-GS provides clinically actionable information regarding patients classified as intermediate risk by the 21-GA and was associated with a change in treatment decision in 282 of these patients (33.6 percent)," the authors write.

Several authors disclosed ties to biopharmaceutical companies, including Agendia Inc., which funded the study.

Abstract/Full Text

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs